Barrett’s Esophagus and Esophageal Adenocarcinoma: A Histopathological Perspective

Cattelan L. Ghazawi F.M. Le M. et al.

Epidemiologic trends and geographic distribution of esophageal cancer in Canada: A national population-based study.

Cancer Med. 9: 401-417Hur C. Miller M. Kong C.Y. et al.

Trends in esophageal adenocarcinoma incidence and mortality.

Cancer. 119: 1149-1158Shaheen N.J. Falk G.W. Iyer P.G. et al.

ACG Clinical Guideline: Diagnosis and management of Barrett’s esophagus.

Am J Gastroenterol. 111: 30-50

Epidemiology of Barrett’s esophagus and esophageal adenocarcinoma - implications for screening and surveillance.

Gastrointest Endosc Clin N Am. 31: 1-26Rustgi A.K. El-Serag H.B.

Esophageal carcinoma.

N Engl J Med. 371: 2499-2509Groulx S. Limburg H. Doull M. et al.

Guideline on screening for esophageal adenocarcinoma in patients with chronic gastroesophageal reflux disease.

Can Med Assoc J. 192: E768-E777Then E.O. Lopez M. Saleem S. et al.

Esophageal cancer: An updated Surveillance Epidemiology and End Results database analysis.

World J Oncol. 11: 55-64Harrison R. Perry I. Haddadin W. et al.

Detection of intestinal metaplasia in Barrett’s esophagus: an observational comparator study suggests the need for a minimum of eight biopsies.

Am J Gastroenterol. 102: 1154-1161Naini B.V. Souza R.F. Odze R.D.

Barrett’s esophagus: a comprehensive and contemporary review for pathologists.

Am J Surg Pathol. 40: e45-e66Coleman H.G. Xie S.H. Lagergren J.

The epidemiology of esophageal adenocarcinoma.

Gastroenterology. 154: 390-405Desai T.K. Krishnan K. Samala N. et al.

The incidence of oesophageal adenocarcinoma in non-dysplastic Barrett’s oesophagus: a meta-analysis.

Gut. 61: 970-976Singh S. Manickam P. Amin A.V. et al.

Incidence of esophageal adenocarcinoma in Barrett’s esophagus with low-grade dysplasia: a systematic review and meta-analysis.

Gastrointest Endosc. 79 (): 897-909Rastogi A. Puli S. El-Serag H.B. et al.

Incidence of esophageal adenocarcinoma in patients with Barrett’s esophagus and high-grade dysplasia: a meta-analysis.

Gastrointest Endosc. 67: 394-398

Barrett’s esophagus and Barrett’s-related dysplasia.

Mod Pathol. 16: 316-324Hopcroft S.A. Shepherd N.A.

The changing role of the pathologist in the management of Barrett’s oesophagus.

Histopathology. 65: 441-455

Chronic peptic ulcers of the œsophagus and ‘œsophagitis.

Br J Surg. 38: 175-182Lowes H. Somarathna T. Shepherd N.A.

Definition, derivation, and diagnosis of Barrett’s esophagus: pathological perspectives.

in: Jansen M. Wright N.A. Stem cells, Pre-neoplasia, and early cancer of the Upper gastrointestinal tract. Springer International Publishing, Switzerland: 111-136Paull A. Trier J.S. Dalton M.D. et al.

The histologic spectrum of Barrett’s esophagus.

N Engl J Med. 295: 476-480Watanabe G. Ajioka Y. Takeuchi M. et al.

Intestinal metaplasia in Barrett’s oesophagus may be an epiphenomenon rather than a preneoplastic condition, and CDX2-positive cardiac-type epithelium is associated with minute Barrett’s tumour.

Histopathology. 66: 201-214Takubo K. Aida J. Naomoto Y. et al.

Cardiac rather than intestinal-type background in endoscopic resection specimens of minute Barrett adenocarcinoma.

Hum Pathol. 40: 65-74

Metaplasia and transdifferentiation: from pure biology to the clinic.

Nat Rev Mol Cell Biol. 8: 369-378

The cell of origin for Barrett’s esophagus.

Science. 373: 737-738Boch J. Shields H. Antonioli D. et al.

Distribution of cytokeratin markers in Barrett’s specialized columnar epithelium.

Gastroenterology. 112: 760-765Aichler M. Seiler C. Tost M. et al.

Origin of pancreatic ductal adenocarcinoma from atypical flat lesions: a comparative study in transgenic mice and human tissues.

J Pathol. 226: 723-734Barbera M. Pietro M di Walker E. et al.

The human squamous oesophagus has widespread capacity for clonal expansion from cells at diverse stages of differentiation.

Gut. 64: 11-19Sarosi G. Brown G. Jaiswal K. et al.

Bone marrow progenitor cells contribute to esophageal regeneration and metaplasia in a rat model of Barrett’s esophagus.

Dis Esophagus. 21: 43-50Aikou S. Aida J. Takubo K. et al.

Columnar metaplasia in a surgical mouse model of gastro-esophageal reflux disease is not derived from bone marrow-derived cell.

Cancer Sci. 104: 1154-1161Leedham S.J. Preston S.L. McDonald S.A.C. et al.

Individual crypt genetic heterogeneity and the origin of metaplastic glandular epithelium in human Barrett’s oesophagus.

Gut. 57: 1041-1048Owen R.P. White M.J. Severson D.T. et al.

Single cell RNA-seq reveals profound transcriptional similarity between Barrett’s oesophagus and oesophageal submucosal glands.

Nat Commun. 9: 4261Nowicki-Osuch K. Zhuang L. Jammula S. et al.

Molecular phenotyping reveals the identity of Barrett’s esophagus and its malignant transition.

Science. 373: 760-767Riddell R.H. Goldman H. Ransohoff D.F. et al.

Dysplasia in inflammatory bowel disease: standardized classification with provisional clinical applications.

Hum Pathol. 14: 931-968van der Wel M.J. Jansen M. Vieth M. et al.

What makes an expert Barrett’s histopathologist?.

in: Jansen M. Wright N.A. Stem cells, Pre-neoplasia, and early cancer of the Upper gastrointestinal tract. Springer International Publishing, Switzerland: 137-159Yin F. Hernandez Gonzalo D. Lai J. et al.

Histopathology of Barrett’s esophagus and early-stage esophageal adenocarcinoma: an updated review.

Gastrointest Disord. 1: 147-163Kumarasinghe M.P. Armstrong M. Foo J. et al.

The modern management of Barrett’s oesophagus and related neoplasia: role of pathology.

Histopathology. 78: 18-38Corsini E.M. Foo W.C. Mitchell K.G. et al.

Esophageal adenocarcinoma with any component of signet ring cells portends poor prognosis and response to neoadjuvant therapy.

J Thorac Cardiovasc Surg. 162: 1404-1412Patel V.R. Hofstetter W.L. Correa A.M. et al.

Signet ring cells in esophageal adenocarcinoma predict poor response to preoperative chemoradiation.

Ann Thorac Surg. 98: 1064-1071Rice T.W. Patil D.T. Blackstone E.H.

8th edition AJCC/UICC staging of cancers of the esophagus and esophagogastric junction: application to clinical practice.

Ann Cardiothorac Surg. 6: 119-130

Examination of surgical specimens of the esophagus.

Arch Pathol Lab Med. 139: 1446-1454Orosey M. Amin M. Cappell M.S.

A 14-year study of 398 esophageal adenocarcinomas diagnosed among 156,256 EGDs performed at two large hospitals: an inlet patch is proposed as a significant risk factor for proximal esophageal adenocarcinoma.

Dig Dis Sci. 63: 452-465Taniere P. Borghi-Scoazec G. Saurin J.C. et al.

Cytokeratin expression in adenocarcinomas of the esophagogastric junction: a comparative study of adenocarcinomas of the distal esophagus and of the proximal stomach.

Am J Surg Pathol. 26: 1213-1221Driessen A. Nafteux P. Lerut T. et al.

Identical cytokeratin expression pattern CK7+/CK20- in esophageal and cardiac cancer: etiopathological and clinical implications.

Mod Pathol. 17: 49-55Shah M.A. Kennedy E.B. Catenacci D.V. et al.

Treatment of locally advanced esophageal carcinoma: ASCO Guideline.

J Clin Oncol. 38: 2677-2694Muir J.A. Marcon N. Aranda-Hernandez J. et al.

Endoscopic mucosal resection (EMR) in Barrett’s esophagus associated neoplasia: recommendations for pathological evaluation and reporting.

Can J Pathol. 7: 25-36Sharma P. Shaheen N.J. Katzka D. et al.

AGA clinical practice update on endoscopic treatment of Barrett’s esophagus with dysplasia and/or early cancer: expert review.

Gastroenterology. 158: 760-769Kumarasinghe M.P. Bourke M.J. Brown I. et al.

Pathological assessment of endoscopic resections of the gastrointestinal tract: a comprehensive clinicopathologic review.

Mod Pathol. 33: 986-1006Othman M.O. Lee J.H. Wang K.

AGA clinical practice update on the utility of endoscopic submucosal dissection in T1b esophageal cancer: expert review.

Clin Gastroenterol Hepatol. 17: 2161-2166Manner H. Pech O. Heldmann Y. et al.

The frequency of lymph node metastasis in early-stage adenocarcinoma of the esophagus with incipient submucosal invasion (pT1b sm1) depending on histological risk patterns.

Surg Endosc. 29: 1888-1896Manner H. Pech O. Heldmann Y. et al.

Efficacy, safety, and long-term results of endoscopic treatment for early stage adenocarcinoma of the esophagus with low-risk sm1 invasion.

Clin Gastroenterol Hepatol. 11: 630-635Nentwich M.F. von Loga K. Reeh M. et al.

Depth of submucosal tumor infiltration and its relevance in lymphatic metastasis formation for T1b squamous cell and adenocarcinomas of the esophagus.

J Gastrointest Surg. 18: 242-249Griffin S.M. Burt A.D. Jennings N.A.

Lymph node metastasis in early esophageal adenocarcinoma.

Ann Surg. 254: 731-737Cen P. Hofstetter W.L. Correa A.M. et al.

Lymphovascular invasion as a tool to further subclassify T1b esophageal adenocarcinoma.

Cancer. 112: 1020-1027Badreddine R.J. Prasad G.A. Lewis J.T. et al.

Depth of submucosal invasion does not predict lymph node metastasis and survival of patients with esophageal carcinoma.

Clin Gastroenterol Hepatol. 8: 248-253Karamchandani D.M. Gonzalez R.S. Westerhoff M. et al.

Measuring depth of invasion of submucosa – invasive adenocarcinoma in oesophageal endoscopic specimens: how good are we?.

Histopathology. 80: 420-429Dunbar K.B. Spechler S.J.

The risk of lymph node metastases in patients with high grade dysplasia or intramucosal carcinoma in Barrett’s esophagus: a systematic review.

Am J Gastroenterol. 107: 850-863Zemler B. May A. Ell C. et al.

Early Barrett’s carcinoma: the depth of infiltration of the tumour correlates with the degree of differentiation, the incidence of lymphatic vessel and venous invasion.

Virchows Archiv. 456: 609-614Estrella J.S. Hofstetter W.L. Correa A.M. et al.

Duplicated muscularis mucosae invasion has similar risk of lymph node metastasis and recurrence-free survival as intramucosal esophageal adenocarcinoma.

Am J Surg Pathol. 35: 1045-1053Kaneshiro D.K. Post J.C. Rybicki L. et al.

Clinical significance of the duplicated muscularis mucosae in Barrett esophagus-related superficial adenocarcinoma.

Am J Surg Pathol. 35: 697-700Chang F. Deere H. Mahadeva U. et al.

Histopathologic examination and reporting of esophageal carcinomas following preoperative neoadjuvant therapy: practical guidelines and current issues.

Am J Clin Pathol. 129: 252-262Wang K.L. Yang Q. Cleary K.R. et al.

The significance of neuroendocrine differentiation in adenocarcinoma of the esophagus and esophagogastric junction after preoperative chemoradiation.

Cancer. 107: 1467-1474Alnaji R.M. Du W. Gabriel E. et al.

Pathologic complete response is an independent predictor of improved survival following neoadjuvant chemoradiation for esophageal adenocarcinoma.

J Gastrointest Surg. 20: 1541-1546Langer R. Ott K. Feith M. et al.

Prognostic significance of histopathological tumor regression after neoadjuvant chemotherapy in esophageal adenocarcinomas.

Mod Pathol. 22: 1555-1563Groth S.S. Burt B.M. Farjah F. et al.

Prognostic value of neoadjuvant treatment response in locally advanced esophageal adenocarcinoma.

J Thorac Cardiovasc Surg. 157: 1682-1693Mandard A.M. Dalibard F. Mandard J.C. et al.

Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlations.

Cancer. 73: 2680-2686

Tumor regression grading of gastrointestinal cancers after neoadjuvant therapy.

Virchows Archiv. 472: 175-186Takeda F.R. Tustumi F. de Almeida Obregon C. et al.

Prognostic value of tumor regression grade based on Ryan score in squamous cell carcinoma and adenocarcinoma of esophagus.

Ann Surg Oncol. 27: 1241-1247Noble F. Lloyd M.A. Turkington R. et al.

Multicentre cohort study to define and validate pathological assessment of response to neoadjuvant therapy in oesophagogastric adenocarcinoma.

Br J Surg. 104: 1816-1828Karamitopoulou E. Thies S. Zlobec I. et al.

Assessment of tumor regression of esophageal adenocarcinomas after neoadjuvant chemotherapy: comparison of 2 commonly used scoring approaches.

Am J Surg Pathol. 38: 1551-1556Hornick J.L. Farraye F.A. Odze R.D.

Prevalence and significance of prominent mucin pools in the esophagus post neoadjuvant chemoradiotherapy for Barrett’s-associated adenocarcinoma.

Am J Surg Pathol. 30: 28-35Spicer J. Benay C. Lee L. et al.

Diagnostic accuracy and utility of intraoperative microscopic margin analysis of gastric and esophageal adenocarcinoma.

Ann Surg Oncol. 21: 2580-2586Chan D.S.Y. Reid T.D. Howell I. et al.

Systematic review and meta-analysis of the influence of circumferential resection margin involvement on survival in patients with operable oesophageal cancer.

Br J Surg. 100: 456-464Thies S. Guldener L. Slotta-Huspenina J. et al.

Impact of peritumoral and intratumoral budding in esophageal adenocarcinomas.

Hum Pathol. 52: 1-8Landau M.S. Hastings S.M. Foxwell T.J. et al.

Tumor budding is associated with an increased risk of lymph node metastasis and poor prognosis in superficial esophageal adenocarcinoma.

Mod Pathol. 27: 1578-1589Lohneis P. Hieggelke L. Gebauer F. et al.

Tumor budding assessed according to the criteria of the International Tumor Budding Consensus Conference determines prognosis in resected esophageal adenocarcinoma.

Virchows Archiv. 478: 393-400Marginean E.C. Dhanpat J.

Pathologic assessment of endoscopic resection specimens with superficial carcinoma of the esophagus: current practice and practical issues.

Ann N Y Acad Sci. 1482: 130-145Nafteux P.R. Lerut A.M. Moons J. et al.

International multicenter study on the impact of extracapsular lymph node involvement in primary surgery adenocarcinoma of the esophagus on overall survival and staging systems.

Ann Surg. 262: 809-816Wang A. Tan Y. Geng X. et al.

Lymphovascular invasion as a poor prognostic indicator in thoracic esophageal carcinoma: a systematic review and meta-analysis.

Dis Esophagus. 32: doy083Lordick F. Mariette C. Haustermans K. et al.

Oesophageal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Ann Oncol. 27: v50-v57Bang Y.J. Van Cutsem E. Feyereislova A. et al.

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.

Lancet. 376: 687-697Hu Y. Bandla S. Godfrey T.E. et al.

HER2 amplification, overexpression and score criteria in esophageal adenocarcinoma.

Mod Pathol. 24: 899-907Yoon H.H. Shi Q. Sukov W.R. et al.

Association of HER2/ErbB2 expression and gene amplification with pathologic features and prognosis in esophageal adenocarcinomas.

Clin Cancer Res. 18: 546-554Bartley A.N. Washington M.K. Ventura C.B. et al.

HER2 testing and clinical decision making in gastroesophageal adenocarcinoma: guideline from the College of American Pathologists, American Society for Clinical Pathology, and American Society of Clinical Oncology.

Am J Clin Pathol. 146: 647-669

留言 (0)

沒有登入
gif